5:31:50Pfizer's Paxlovid fuels Q3 earnings
From the creator
As Pfizer (PFE) continues its ongoing battle with activist investor Starboard Value, Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins the Morning Brief to discuss how it may weigh on the company's outlook. The pharmaceutical giant beat third quarter earnings results with revenue growing 23% year-over-year to $17.7 billion. One of the major issues Starboard Value has been critical of is Pfizer's spending. Shibutani explains: "I think the COVID-complex revenue trajectory gave them tremendous access to resources. And with that, they were able to apply that to thinking about how to rebuild the post-COVID revenue profile for the company." Pfizer went forward with mergers and acquisitions, which had varying degrees of success. "That return on investment component is what is, I think, being questioned on terms of the overall operating expense profile," he tells Yahoo Finance. Shibutani adds, "The company has been very actively engaged in a clearly announced cost realignment program, and we're seeing those results over the last several quarters now where the operating expense levels, spending on SI&A (selling, informational, and administrative) and R&D (research and development) has come in below expectations. So it's a combination of factors here." Starboard Value has also questioned Chairman and CEO Albert Bourla's role, advocating for his replacement. Bourla recently gained the support of former Pfizer CEO Ian Read and former CFO Frank
Published 2024-10-29 · Watch on YouTube ↗
Availability and playback restrictions are controlled by the original channel.





